John K. C. Lim

Anticancer Activity of CX-3543: A Direct Inhibitor of rRNA Biogenesis

Denis Drygin, Adam Siddiqui-Jain, Sean O’Brien et al. · Cancer Research · 2009 · 594 citations

Life Sciences, Molecular Biology, Oncology +17

Repotrectinib (TPX-0005) Is a Next-Generation ROS1/TRK/ALK Inhibitor That Potently Inhibits ROS1/TRK/ALK Solvent- Front Mutations

Alexander Drilon, Sai‐Hong Ignatius Ou, Byoung Chul Cho et al. · Cancer Discovery · 2018 · 480 citations · Full text

Medicine, Oncology, Pharmacology +15

First-in-Human RNA Polymerase I Transcription Inhibitor CX-5461 in Patients with Advanced Hematologic Cancers: Results of a Phase I Dose-Escalation Study

Amit Khot, Natalie Brajanovski, Donald P. Cameron et al. · Cancer Discovery · 2019 · 203 citations

Medicine, Oncology, Pharmacology +15

CK2 Inhibitor CX-4945 Suppresses DNA Repair Response Triggered by DNA-Targeted Anticancer Drugs and Augments Efficacy: Mechanistic Rationale for Drug Combination Therapy

Adam Siddiqui-Jain, Joshua Bliesath, Diwata Macalino et al. · Molecular Cancer Therapeutics · 2012 · 98 citations

Medicine, Oncology, Pharmacology +17

Combined inhibition of EGFR and CK2 augments the attenuation of PI3K-Akt-mTOR signaling and the killing of cancer cells

Joshua Bliesath, Nanni Huser, Mayuko Omori et al. · Cancer Letters · 2012 · 72 citations

Medicine, Oncology, Pharmacology +14